Search Results

DYSIS Medical Inc., an emerging biophotonics company focused on providing innovative cervical mapping technology designed to help healthcare professionals identify precancerous lesions on the cervix, announced the appointment of Chris Arnold as Chief Commercial Officer.

DYSIS Medical Inc. is excited to announce the launch of DYSIS® View, a compact and portable colposcope, which includes the company’s innovative computer-aided cervical mapping technology that helps healthcare professionals detect cervical lesions more clearly.

DYSIS Smart Colposcopy is computer-aided cervical imaging that adds the DYSISmap to a standard colposcopic assessment with clinical studies showing that it helps clinicians increase detection of high-grade cervical lesions

Feb. 10, 2020 15:00 UTC ALPHARETTA, Ga.--( BUSINESS WIRE )-- DYSIS Medical today announced that John Pedersen has assumed the position of Board Chairman. Pedersen most recently served as CEO of Augmenix, a privately held company that manufactured and sold minimally invasive hydrogel products to improve outcomes following cancer radiotherapy. Augmenix was sold to Boston Scientific in 2018 for $600M. Prior to joining Augmenix, Pedersen served as a Senior Healthcare Advisor for tw

DYSIS Medical announced that the American Medical Association (AMA) has granted a Category I, Current Procedural Terminology (CPT) add-on code specifically for computer aided mapping of the cervix during colposcopy.

DYSIS Medical Ltd, the developer of the innovative DYSIS Ultra Colposcope used in cervical cancer screening, announced today the appointment of Darin Hammers as Chief Executive Officer and a member of the board of directors.

DYSIS Medical Ltd announces today the completion of an £18 million ($25 million) investment.

DYSIS Medical Ltd announces that the National Institute for Health and Care Excellence (NICE) has updated its original 2012 guidance on adjunctive colposcopy technologies.